GAFA
BNTX icon

Garton & Associates Financial Advisors’s BioNTech BNTX Stock Holding History

Garton & Associates Financial Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed -$952 – 193
2025
Q4 		$952 Buy
+10
New +$1.01K ﹤0.01% 1139

Other funds holding BNTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Garton & Associates Financial Advisors's BNTX Position: Q1 2026 in Review

Garton & Associates Financial Advisors sold out of BioNTech (BNTX) in Q1 2026, closing a stake of 10 shares — an estimated $952 sold.

Garton & Associates Financial Advisors first reported a position in BNTX in Q4 2025 and held it in 1 quarter. The position peaked at $952 in Q4 2025. 272 funds tracked by Wall St. Rank hold BNTX as of Q1 2026.

  • Garton & Associates Financial Advisors reported no remaining BioNTech position as of Q1 2026 after selling out during the quarter.
  • Garton & Associates Financial Advisors sold 10 BioNTech shares in Q1 2026, an estimated $952.
  • Garton & Associates Financial Advisors first reported a position in BioNTech in Q4 2025 and held it in 1 quarter.
  • Garton & Associates Financial Advisors's BioNTech position peaked at $952 in Q4 2025.
  • 272 funds tracked by Wall St. Rank held BioNTech as of Q1 2026.

Based on Garton & Associates Financial Advisors's 13F filing for Q1 2026, filed 11 May 2026.